title: [Results of 125-iodine seed implant with preplanning system in 250 patients with prostate cancer].
abstract: BACKGROUND
  We review the experience with prostate carcinoma patients treated with permanent implants of 125-I seeds and the outcome eight years after the beginning of this technique.
  
  
  METHODS
  From 2002 to 2007 we have performed 250 implants with LDR brachytherapy with RapidStrand(®) and preplanning system. Mean age was 68 (49-78). Mean PSA was 7.32 (2.31 - 14.6). T1-T2a was the stage in 98%, and Gleason ≤ 6 in 96%. Low risk cases were 81% and intermediate risk 19% (ten of them received 46 Gy EBRT). Hormonal treatment was used in 42%.
  
  
  RESULTS
  With a mean follow-up of 48 months, 14 patients (5.7%) showed biochemical failure (BF). Eleven patients (4.5%) with theoretical BF were observed and PSA decreased without treatment. Actuarial PSA relapse-free survival at 5 years was 91%, (92% low risk, 86% intermediate cases), and 92% vs 81% with PSA <10 vs >10 (p<0.05). Rectum complications were G2 in 0.6%. A urinary catheter was necessary in 6.5%. Sexual function was conserved in 60%. Mean V100 was 89% and D90 143 Gy.
  
  
  CONCLUSIONS
  The outcome of patients with low risk prostate carcinoma treated with I-125 seed is very good with very low complications rate. Cases with PSA bounces should be controlled before starting a salvage treatment.
authors.affiliation: Servicio de Oncología Radioterápica, Fundación Instituto Valenciano de Oncología (IVO), Valencia, España. jguinot@fivo.org
authors.forename: J L
authors.initials: JL
authors.lastname: Guinot
authors.forename: J V
authors.initials: JV
authors.lastname: Ricós
authors.forename: J
authors.initials: J
authors.lastname: Gimeno
authors.forename: M I
authors.initials: MI
authors.lastname: Tortajada
authors.forename: M
authors.initials: M
authors.lastname: Carrascosa
authors.forename: M
authors.initials: M
authors.lastname: Santos
authors.forename: J
authors.initials: J
authors.lastname: Casanova
authors.forename: P
authors.initials: P
authors.lastname: Soler
authors.forename: V
authors.initials: V
authors.lastname: Crispín
authors.forename: L
authors.initials: L
authors.lastname: Arribas
mesh_terms: D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy / Q000532:radiotherapy*; D000368:Aged; D000813:Anilides / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001918:Brachytherapy; D003131:Combined Modality Therapy; D003199:Computer Systems; D006801:Humans; D007457:Iodine Radioisotopes / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000532:radiotherapy*; D015641:Radiography, Interventional; D011880:Radiotherapy Planning, Computer-Assisted; D012189:Retrospective Studies; D014105:Tosyl Compounds / Q000627:therapeutic use; D016896:Treatment Outcome
chemical_list: D000813:Anilides; D018931:Antineoplastic Agents, Hormonal; D007457:Iodine Radioisotopes; D009570:Nitriles; D014105:Tosyl Compounds; C053541:bicalutamide; D017430:Prostate-Specific Antigen